Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Notice of Results

21st Mar 2025 07:00

RNS Number : 5779B
hVIVO PLC
21 March 2025
 

hVIVO plc

("hVIVO", the "Company" or the "Group")

 

Notice of results

 

hVIVO plc (AIM: HVO), a fast-growing early-stage Contract Research Organisation ("CRO") and the world leader in human challenge clinical trials, announces that it will release its final results for the year ended 31 December 2024 on Thursday 10 April 2025.

 

Analyst briefing

 

A briefing open to equity research analysts will take place on Thursday 10 April 2025 at 11.00am BST. To register and for more details please contact Walbrook PR on [email protected].

 

Investor presentation

 

Yamin 'Mo' Khan, Chief Executive Officer, and Stephen Pinkerton, Chief Financial Officer, will provide a live presentation relating to the final results via the Investor Meet Company platform on Thursday 10 April 2025 at 6.00pm BST.

 

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.

 

Investors can sign up to Investor Meet Company for free and add to meet hVIVO here. Investors who already follow hVIVO on the Investor Meet Company platform will automatically be invited.

 

 

For further information please contact:

 

hVIVO plc

+44 (0)20 7756 1300

Yamin 'Mo' Khan, Chief Executive Officer

Stephen Pinkerton, Chief Financial Officer

Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)

+44 (0)20 7220 0500

Geoff Nash, Camilla Hume, Harriet Ward

Nigel Birks - Life Science Specialist Sales

Louise Talbot - Sales

Peel Hunt LLP (Joint Broker)

+44 (0)20 7418 8900

James Steel, Dr Christopher Golden

Davy (Joint Broker)

+353 (0) 1 679 6363

Anthony Farrell, Niall Gilchrist

Walbrook PR (Financial PR & IR)

Paul McManus / Phillip Marriage /Louis Ashe-Jepson

+44 (0)20 7933 8780 or [email protected]

+44 (0)7980 541 893 / +44 (0)7867 984 082 /+44 (0)7747 515 393

 

 

 

Notes to Editors

 

hVIVO plc (Ticker: HVO) is a rapidly growing early-stage Contract Research Organisation (CRO) and the global leader in human challenge trials. The company delivers end-to-end clinical development services to a diverse and expanding client base, including seven of the world's ten largest biopharma companies.

 

hVIVO specialises in conducting human challenge trials across multiple infectious and respiratory indications, leveraging its state-of-the-art quarantine facility in London-the largest of its kind worldwide. The company also offers comprehensive virology and immunology laboratory services under the hLAB brand.

 

Through its German subsidiary, CRS, hVIVO operates a 120-bed capacity across Mannheim and Kiel, providing early-phase clinical trial services, including first-in-human and proof-of-concept studies. Its second subsidiary, Venn Life Sciences, offers Early Drug Development Consulting and Biometry services to the biopharma sector.

 

The Group provides fully integrated drug development solutions from preclinical stages through Phase II trials, alongside patient recruitment via FluCamp. Additionally, its five clinical sites support outpatient Phase II and III trials, ensuring a seamless and efficient pathway from discovery to late-stage development.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NORBCGDXLSDDGUG

Related Shares:

hVIVO
FTSE 100 Latest
Value8,658.85
Change-7.27